Pharma R&D
Predict immunotherapy response from live tumor biopsies
De-risk pipeline decisions, optimize trial design, and identify likely responders.
Functional immunotherapy response prediction
Standard of care biopsies are prepared using a proprietary automated cutting instrument and gel, keeping tissue alive throughout assessment on the elive™ platform.
Mitigating the challenges of heterogeneity and low tissue volume, our sequential treatment strategy accurately assesses changes in cytokine response.
Clinicians receive elive test reports via a secure, cloud-based web application.
Researchers and drug developers receive a custom report based on project requirements. In addition to a report summarizing key findings, we provide raw data to facilitate in-house analysis.
Our partnership model adapts to how you intend to use elive. Options include deploying the platform in your own lab, commissioning custom studies performed in ours, purchasing or leasing individual components, or joining our early access program for the elive Test. Contact us to explore what best fits your needs.
